Total Voting Rights

RNS Number : 6615P
Hutchison China Meditech Limited
31 May 2018
 

Total Voting Rights



London: Thursday, May 31, 2018: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) hereby notifies the market that as at May 31, 2018, the issued share capital of Chi-Med consisted of 66,515,756 ordinary shares of US$1.00 each, with each share carrying one right to vote and with no shares held in treasury.

 

The above figure of 66,515,756 may be used by shareholders as the denominator for the calculations by which they could determine if they are required to notify their interest in, or a change to their interest in, Chi-Med under the Financial Conduct Authority's Disclosure Rules and Transparency Rules.

 

For illustrative purposes only, the 66,515,756 ordinary shares would be equivalent to 66,515,756 CREST depositary interests (each equating to one ordinary share) which are traded on AIM or, if the CREST depositary interests were converted in their entirety, equivalent to 133,031,512 American depositary shares (each equating to one-half of one ordinary share) which are traded on Nasdaq.

 

 

About Chi-Med

 

Chi-Med is an innovative biopharmaceutical company which researches, develops, manufactures and sells pharmaceuticals and healthcare products.  Its Innovation Platform, Hutchison MediPharma Limited, focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market.  Its Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products in China.

 

Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 1).  For more information, please visit: www.chi-med.com.

 

 

CONTACTS

 

Investor Enquiries



Mark Lee, Senior Vice President, Corporate Finance & Development

+852 2121 8200





U.K. & International Media Enquiries



Anthony Carlisle, Citigate Dewe Rogerson

+44 7973 611 888 (Mobile)

anthony.carlisle@cdrconsultancy.co.uk




U.S. Based Media Enquiries



Brad Miles, Solebury Trout

+1 (917) 570 7340 (Mobile)

bmiles@troutgroup.com

Susan Duffy, Solebury Trout

+1 (917) 499 8887 (Mobile)

sduffy@troutgroup.com




Investor Relations



Xuan Yang, Solebury Trout

+1 (415) 971 9412 (Mobile)

xyang@troutgroup.com

David Dible, Citigate Dewe Rogerson  

+44 7967 566 919 (Mobile)

david.dible@citigatedewerogerson.com




Panmure Gordon (UK) Limited



Richard Gray / Andrew Potts

+44 (20) 7886 2500


 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TVREAPSEDAAPEEF
UK 100